Protekt Therapeutics
PKR Inhibition for Treating Neurodegenerative Diseases
Company Name | Updating Date | Neurotech Category | Market Category | Target Market | Technologies | Company Founded Year | Company Number of Employees |
|---|---|---|---|---|---|---|---|
Protekt Therapeutics | 02/07/2022 | NeuroPharmacology | NeuroBioTechnology | Biotechnology & Biopharmaceutical | Medical use (pharma, nerve damage rehabilitation, neurodiagnostics. inc. early diagnosis) | Biochemical: pharmacological drugs (Developing drugs) | 01/01/2014 | "1-10" |
Protekt Therapeutics is a biopharmaceutical company aiming to identify and develop a potent and selective oral PKR inhibitor (PKRi) to treat cognitive disorders such as Alzheimer’s disease and mild cognitive impairment. PKR is a stress and proapoptotic kinase that phosphorylates eIF2α, a key protein in the translation machinery, and results in inhibition of protein synthesis and impaired memory consolidation.
PKR is also activated during apoptosis, autophagy, neuroinflammation, and Aβ peptide toxicity, which are prominent features of Alzheimer’s Disease (AD). Therefore, PKR inhibition offers a novel and promising disease-modifying mechanism for modulating multiple key processes in AD and other neurodegenerative diseases.
Protekt Therapeutics was established in the FutuRx Incubator in December 2015.